ERBB2 and carcinoma: In their study, HER-2/neu positivity expression was observed in 50% of cases of SCCs, 20% of poorly differentiated carcinomas, 18.1% of well-differentiated carcinomas, and 3.4% of moderately differentiated carcinomas [13].